Abstract
Fat accumulations a typical phenomenon in the pathogenesis of Type 2 diabetes. Also Type 1 diabetics are getting obese these days living in an environment with typical caloric overfeeding and lowphysical activity. Weight reduction is an important part of therapy in all obese diabetic patients. Orlistat is the only accessible antiobesity drag today. Weight neutral antidiabetics like metformin and DPP-4 inhibitors can be also used. Incretin analogues (exenatide and liraglutide) are also very important drags inducing weight loss in diabetic and also in nondiabetic patients. Insulin therapy causes mostly weight gain. Long acting insulin analogues are able to induce small weight loss in Type 1 diabetes or only a small weight increase or weight loss in Type 2 diabetic patients. Procedures of bariatric surgery are very important in the treatment being able to induce remission of Type 2 diabetes. Weight reduction can be supported also using the new class of antiadiabetic drugs- SGLT inhibitors which are blocking glucose absorption in kidneys. The use of new incretine analogues injected at the interval of one to two weeks is the most important strategy for the treatment of obese Type 2 diabetic patients and perhaps also of Type 1 diabetic patients even in combination with insulin.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Skrha J. In the name of Czech Diabetes Society committee: Diabetes mellitus—epidemiological study in Czech republic DMEV 2005; 8:5–12.
Byrne Ch, Wild SH, ed. The Metabolic Syndrome, 2nd ed. Chichester: Wi1ey, 2011.
Ganz M, ed. Prevention of Type 2 Diabetes. Chichester: Wiley, 2005.
Nathan DM, Davidson MB, DeFronzo RA et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007: 30(3):753–759.
Sjöström CD, Lissner L, Wedel H et al. Reduction in incidence of diabetes, hypertension andlipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999; 7(5):477–484.
Lean ME, Powrie JK, Anderson AS et al. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990; 7(3):228–233.
Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577–1589.
Buchwald H, Estok R, Fahrbach K et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122(3):248–256.
Fried M, Ribaric G, Buchwald JN et al. Metabolic surgery for the treatment of type 2 diabetes in patients with BMI <35 kg/m2: an integrative review of early studies. Obes Surg 2010; 20(6):776–790.
Regensteiner JG, Reusch JEB, Stewart K et al. Diabetes and Exercise. New York:Humana Press, 2009.
Anderson JW. Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage. Expert Opin Pharmacother 2007; 8(11): 1733–1742.
Torgcrson JS, Hauptman J, Boldrin MN et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27(1):155–161.
Smith SR, Weissman NJ, Anderson CM et al. Multiccnter, placebo-controlled trial of lorcascrin for weight management. N Engl J Med2010; 363(3):245–256.
Goldberg RB, Temprosa M, Haffner S et al. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care 2009; 32(4):726–732.
Martin S, Kolb H, Beuth J et al. Change in patients’ body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study. Diabetologia 2003; 46(12):1611–1617.
Plank J, Bodenlenz M, Sinner F et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005; 28(5):1107–1112.
Schreiber SA, Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab 2007; 9(l):31–8.
List JF, Woo V, Morales E et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32(4):650–657.
Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011; 13(1):7–18.
Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24(l):275–286.
Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374(9701): 1606–1616.
Bhushan R. Elkind-Hirsch KE, Bhushan M et al. Exenatide use in the management of metabolic syndrome: a retrospective database study. Endocr Pract 2008; 14(8):993–999.
Shyangdan DS, Royle PL, Clar C et al. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord 2010; 10:20.e-publikace.
Ratner RE, Rosenstock J, Boka G et al. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med 2010; 27(9):1024–1032.
Christensen M, Knop FK, Holst JJ et al. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs 2009; 12(8):503–513.
Taylor K et al. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord 2011; 11(1):9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Landes Bioscience and Springer Science+Business Media
About this chapter
Cite this chapter
Svačina, Š. (2013). Treatment of Obese Diabetics. In: Ahmad, S.I. (eds) Diabetes. Advances in Experimental Medicine and Biology, vol 771. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5441-0_32
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5441-0_32
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5440-3
Online ISBN: 978-1-4614-5441-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)